Certolizumab pegol for the management of Crohn's disease in adults

Clinical Therapeutics

Volumn 31, Issue 6, 2009, Pages 1158-1176

  Rivkin, Anastasia ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

anti TNF agent; biologic agent; certolizumab pegol; Crohn's disease

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVE VACCINE; MYCOPHENOLIC ACID; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ADD ON THERAPY; ADULT; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTHRALGIA; CLINICAL TRIAL; CROHN DISEASE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEART FAILURE; HUMAN; IMMUNOGENICITY; INFECTION RISK; INJECTION SITE REACTION; LIVER FAILURE; LUNG CANCER; LUNG TUBERCULOSIS; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPPORTUNISTIC INFECTION; PERIANAL ABSCESS; RECOMMENDED DRUG DOSE; RECTUM CARCINOMA; REMISSION; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; POLYETHYLENE GLYCOLS; REMISSION INDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 68649087166     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.06.015     Document Type: Review

References (56)

1. Friedman R., and Blumberg S. Inflammatory bowel disease. In: Fauci A.S., Braunwald E., Kasper D.L., et al. (Eds). Harrison's Principles of Internal Medicine. 17th ed (2008), McGraw-Hill Medical, New York, NY
2. Loftus C.G., Loftus Jr. E.V., Harmsen W.S., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 13 (2007) 254-261
3. Vind I., Riis L., Jess T., et al., the DCCD study group. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: A population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 101 (2006) 1274-1282
4. Loftus Jr. E.V., Silverstein M.D., Sandborn W.J., et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival [published correction appears in Gastroenterology. 1999;116:1507]. Gastroenterology 114 (1998) 1161-1168
5. Loftus Jr. E.V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 126 (2004) 1504-1517
6. American Gastroenterological Association. The burden of gastrointestinal diseases. http://www.gastro.org/user-assets/Documents/burden-report.pdf Accessed March 10, 2009
7. Loftus E.V., Schoenfeld P., and Sandborn W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: A systematic review. Aliment Pharmacol Ther. 16 (2002) 51-60
8. Brown S.J., and Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol. 102 (2007) 2058-2069
9. Büning C., Genschel J., Bühner S., et al. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther. 19 (2004) 1073-1078
10. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
11. Hanauer S.B., Sandborn W., and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 96 (2001) 635-643
12. Lichtenstein G.R., Hanauer S.B., Sandborn W.J., and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol. 104 (2009) 465-483 quiz 464, 484
13. Targan S.R., and Karp L.C. Inflammatory bowel disease diagnosis, evaluation and classification: State-of-the-art approach. Curr Opin Gastroenterol. 23 (2007) 390-394
14. Breese E.J., Michie C.A., Nicholls S.W., et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106 (1994) 1455-1466
15. MacDermott R.P., Sanderson I.R., and Reinecker H.C. The central role of chemokines (chemotactic cytokines) in the immu-nopathogenesis of ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 4 (1998) 54-67
16. Noguchi M., Hiwatashi N., Liu Z., and Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut. 43 (1998) 203-209
17. Murch S.H., Lamkin V.A., Savage M.O., et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 32 (1991) 913-917
18. Braegger C.P., Nicholls S., Murch S.H., et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339 (1992) 89-91
19. Clark M., Colombel J.F., Feagan B.C., et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 133 (2007) 312-339
20. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeST study): A randomized, controlled trial. Arthritis Rheum. 52 (2005) 3381-3390
21. Hommes D., Baert F., van Assche G., et al. Management of recent onset Crohn's disease: A controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology 129 (2005) 371
22. Sandborn W.J., Feagan B.G., Hanauer S.B., et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 122 (2002) 512-530
23. Love J.R., Irvine E.J., and Fedorak R.N. Quality of life in inflammatory bowel disease. J Clin Gastroenterol. 14 (1992) 15-19
24. Irvine E.J., Feagan B., Rochon J., et al., the Canadian Crohn's Relapse Prevention Trial Study Group. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 106 (1994) 287-296
25. Weir N., Athwal D., and Brown D. A new generation of high-affinity humanized PEGylated Fab fragment antitumor necrosis factor-monoclonal antibodies. Therapy 3 (2006) 535-545
26. Nesbitt A., Fossati G., Bergin M., et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 13 (2007) 1323-1332
27. Fossati G., and Nesbitt A. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cyto-toxicity by the anti-TNF agents adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870). Am J Gastroenterol. 100 Suppl (2005) S299 Abstract 807
28. Fossati G., and Nesbitt A. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am J Gastroenterol. 100 Suppl (2005) S298 Abstract 806
29. Baker M., and Stephens S. Investigation of the pharmacokinetic properties of certolizumab pegol, an anti-TNF agent. Am J Gastroenterol. 101 Suppl (2006) S437 Abstract 1117
30. Cimzia (certolizumab pegol) [package insert] (2008), UCB, Inc, Smyrna, Ga
31. Sandborn W.J., Feagan B.G., Stoinov S., et al., the PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 357 (2007) 228-238
32. Schreiber S., Khaliq-Kareemi M., Lawrance I.C., et al., the PRECISE 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease [published correction appears in N Engl J Med. 2007;357:1357]. N Engl J Med. 357 (2007) 239-250
33. Schreiber S., Rutgeerts P., Fedorak R.N., et al., the CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease [published correction appears in Gastroenterology. 2005;129:1808]. Gastroenterology 129 (2005) 807-818
34. Winter T.A., Wright J., Ghosh S., et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: An exploratory study. Aliment Pharmacol Ther. 20 (2004) 1337-1346
35. Gramlick A., Fossati G., and Nesbitt A. Neutralization of soluble and membrane tumor necrosis factor-alpha (TNF-alpha) by infliximab, adalimumab, or certolizumab pegol using P55 or P75 TNF-alpha receptor-specific bioassays. Gastroenterology 130 Suppl (2006) A697 Abstract W1634
36. Lewis J.D. C-reactive protein: Anti-placebo or predictor of response. Gastroenterology 129 (2005) 1114-1116
37. Keystone E., Choy E.H., Kalden J., et al. CDP870, a novel pegylated humanized TNF-alpha inhibitor, is effective in treating the signs and symptoms of rheumatoid arthritis (RA). Presented at: 65th Annual Scientific Meeting of the American College of Rheumatology. San Francisco, Calif; November 11-15 (2001)
38. Hanauer S.B., Schreiber S., Thomsen O.O., et al. T1129 predictors of response in patients with active Crohn's Disease treated with certolizumab pegol: A multiple regression analysis of PRECISE 2 data. Gastroenterology 134 Suppl 1 (2008) A489 Abstract
39. Schreiber S., Panes J., Mason D., et al. T1133 efficacy and tolerability of certolizumab pegol are sustained over 18 months: Data from PRECISE 2 and its extension studies (PRECISE 3 and 4). Gastroenterology 134 Suppl 1 (2008) A490 Abstract
40. Sandborn W.J., Lichtenstein G.R., Schreiber S., et al. The long-term, 30 months, efficacy and tolerability of certolizumab pegol therapy for Crohn's Disease. Am J Gastroenterol. 103 Suppl 1 (2008) S429 Abstract 1099
41. Colombel J.F., and Hebuterne X. Endoscopic mucosal improvement in patients with active Crohn's Disease treated with certolizumab pegol: First results of the MUSIC clinical trial. Am J Gastroenterol. 103 Suppl 1 (2008) S423 Abstract 1107
42. National Institutes of Health. http://www.clinicaltrials.gov Accessed June 15, 2009
43. Lichtenstein G.R., Colombel J.F., Bloomfield R., et al. Long-term safety of an anti-TNF drug by duration of exposure compared to non-anti-TNF exposed patients with Crohn's disease: Novel data from the certolizumab pegol development program. Gastroenterology 143 Suppl 1 (2008) A68 Abstract
44. Colombel J.F., Schreiber S., Rutgeerts P., et al. Long-term safety of certolizumab pegol in Crohn's disease: Integrated safety findings on serious adverse events of special interest. Am J Gastroenterol. 103 Suppl 1 (2008) S430 Abstract 1101
45. US Food and Drug Administration. Information for healthcare professionals: Cimzia (certolizumab pegol), Enbrel (etanercept), Humira (adalimumab), and Remicade (infliximab). http://www.fda.gov/cder/drug/InfoSheets/HCP/TNF_blockersHCP.htm Accessed March 10, 2009
46. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132 (2007) 52-65
47. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al., the ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 359 (2002) 1541-1549
48. Targan S.R., Hanauer S.B., van Deventer S.J., et al., the Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 337 (1997) 1029-1035
49. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial. Gastroenterology 130 (2006) 323-333 quiz 591
50. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann Intern Med. 146 (2007) 829-838
51. Fernandez-Blanco I., and Hinojosa J. Efficacy of intensification therapy with certolizumab pegol in Crohn's disease patients included in a compassionate-use program. Am J Gastroenterol. 103 Suppl 1 (2008) S427
52. Domenech E., Cabriada J.L., Bernal A., et al. Certolizumab pegol therapy in patient with Crohn's disease with previous loss of response to 2 anti-TNF agents. Am J Gastroenterol. 103 Suppl 1 (2008) S429 Abstract 1098
53. Vermeire S., Abreu M., D'Haens G., et al. Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: Open-label induction preliminary results of the WELCOME study. Gastroenterology 134 Suppl 1 (2008) A67 Abstract 494
54. Abreu M., Sandborn W.J., D'Haens G., et al. Certolizumab pegol is efficacious in Crohn's disease patients who have failed infliximab regardless of concomitant therapy or reason for failure. Am J Gastroenterol. 103 Suppl 1 (2008) S430 Abstract 1103
55. Red Book September 2008 Update (2008), Thomson Healthcare, Montvale, NJ
56. Red Book 2008 (2008), Thomson Healthcare, Montvale, NJ